An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells

British Journal of Cancer

Volumn 105, Issue 10, 2011, Pages 1522-1532

  Yashiro, M ^a   Qiu, H ^a,b   Hasegawa, T ^a   Zhang, X ^a,c   Matsuzaki, T ^a   Hirakawa, K ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

chemoresistance; combination therapy; EGFR inhibitor; gastric cancer; irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; CASPASE 6; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEFITINIB; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENES, ERBB-2; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 80755179252     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.397     Document Type: Article

References (40)

1. Arnold D, Peinert S, Voigt W, Schmoll HJ (2006) Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 11: 602-611 (Pubitemid 43967615)
2. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T (2006a) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297-3305 (Pubitemid 43933772)
3. Becker JC, Muller-Tidow C, Stolte M, Fujimori T, Tidow N, Ilea AM, Brandts C, Tickenbrock L, Serve H, Berdel WE, Domschke W, Pohle T (2006b) Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int J Oncol 29: 615-623
4. Bugat R (2003) Irinotecan in the treatment of gastric cancer. Ann Oncol 14(Suppl 2): ii37-ii40 (Pubitemid 36874137)
5. Chang GC, Yu CT, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ, Hsu SL (2008) An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarci-noma A549 cells. Eur J Pharmacol 600: 37-44
6. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
7. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970 (Pubitemid 32963812)
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
9. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby Jr CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914
10. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R (2005) Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11: 1572-1578 (Pubitemid 40315242)
11. Farhat FS (2007) A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 24: 137-146 (Pubitemid 350139221)
12. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47
13. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31: 1458-1468 (Pubitemid 46945355)
14. Gozuacik D, Kimchi A (2006) DAPk protein family and cancer. Autophagy 2: 74-79
15. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH (2008) EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746 (Pubitemid 351600058)
16. Kishida O, Miyazaki Y, Murayama Y, Ogasa M, Miyazaki T, Yamamoto T, Watabe K, Tsutsui S, Kiyohara T, Shimomura I, Shinomura Y (2005) Gefitinib ('Iressa', ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 55: 393-403 (Pubitemid 40379264)
17. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA (2004) The in vitro effect of gefitinib (0Iressa0) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4: 83
18. Kogel D, Prehn JH, Scheidtmann KH (2001) The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game. Bioessays 23: 352-358 (Pubitemid 32285760)
19. Kogel D, Reimertz C, Dussmann H, Mech P, Scheidtmann KH, Prehn JH (2003) The death associated protein (DAP) kinase homologue Dlk/ZIP kinase induces p19ARF-and p53-independent apoptosis. Eur J Cancer 39: 249-256 (Pubitemid 36057076)
20. Korzeniewska-Dyl I (2008) Caspases - a new target in inflammation and cancer therapy?. Pol Merkur Lekarski 24: 5-7
21. LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD (2009) The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 125: 2957-2969
22. Liakakos T, Xeropotamos N, Ziogas D, Roukos D (2008) EGFR as a prognostic marker for gastric cancer. World J Surg 32: 1225-1226; author reply 1227-1229
23. Marth C, Daxenbichler G, Dapunt O (1986) Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 77: 1197-1202 (Pubitemid 17005094)
24. Namiki Y, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J, Fujise K (2006) Preclinical study of a 'tailor-made' combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118: 1545-1555
25. Network NCC (1998) NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park) 12: 179-223
26. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9-15 (Pubitemid 32938124)
27. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45
28. Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 83-105
29. Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC (2007) p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res 67: 1163-1169
30. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J (2006) Pharmacody-namic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 24: 4309-4316 (Pubitemid 46630789)
31. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208 (Pubitemid 41079832)
32. Segal NH, Saltz LB (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60: 207-219
33. Takemura S, Yashiro M, Sunami T, Tendo M, Hirakawa K (2004) Novel models for human scirrhous gastric carcinoma in vivo. Cancer Sci 95: 893-900 (Pubitemid 40045524)
34. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94: 792-797
35. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC (2007) Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016 (Pubitemid 46514736)
36. Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851 (Pubitemid 36040772)
37. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1995) Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 72: 1200-1210
38. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY (2010) Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 251: 254-260
39. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, Nakanishi H (2006) Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 95: 1504-1513 (Pubitemid 44863353)
40. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K (2010) Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 30: 915-921